Last reviewed · How we verify
NCT04427228: MIGRAINE
Single vs Multi-fraction SRS Patients on Immunotherapy
Withdrawn
Phase 2
Last updated 28 August 2023
What this trial tests
Phase 2 trial testing Radiosurgery Single Treatment in Brain Cancer. Withdrawn.
Timeline
29 June 2020
Primary endpoint
12 December 2022
12 December 2022
12 December 2022
Quick facts
| Lead sponsor | University of Chicago |
|---|---|
| Phase | Phase 2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Start date | 29 June 2020 |
| Primary completion | 12 December 2022 |
| Estimated completion | 12 December 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Radiosurgery Single Treatment
- Radiosurgery Three Treatments
Conditions studied
- Brain Cancer — all drugs for Brain Cancer →
- Brain Metastases — all drugs for Brain Metastases →
Sponsor
University of Chicago
Who can join
18 and older, any sex, with Brain Cancer or Brain Metastases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is meant to compare different surgical approaches to brain cancer.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Modern Radiation Therapy for the Management of Brain Metastases From Non-Small Cell Lung Cancer: Current Approaches and Future Directions.
Mantovani C, Gastino A, Cerrato M, Badellino S, et al · · 2021 · cited 37× · PMID 34796118 · DOI 10.3389/fonc.2021.772789 -
Opportunities for improving brain cancer treatment outcomes through imaging-based mathematical modeling of the delivery of radiotherapy and immunotherapy.
Hormuth DA, Farhat M, Christenson C, Curl B, et al · · 2022 · cited 26× · PMID 35654212 · DOI 10.1016/j.addr.2022.114367 -
Immune Checkpoints Inhibitors and SRS/SBRT Synergy in Metastatic Non-Small-Cell Lung Cancer and Melanoma: A Systematic Review.
Rodríguez Plá M, Dualde Beltrán D, Ferrer Albiach E. · · 2021 · cited 24× · PMID 34769050 · DOI 10.3390/ijms222111621 -
Optimizing the synergy between stereotactic radiosurgery and immunotherapy for brain metastases.
Yoo KH, Park DJ, Choi JH, Marianayagam NJ, et al · · 2023 · cited 14× · PMID 37637032 · DOI 10.3389/fonc.2023.1223599 -
Modern Stereotactic Radiotherapy for Brain Metastases from Lung Cancer: Current Trends and Future Perspectives Based on Integrated Translational Approaches.
Levis M, Gastino A, De Giorgi G, Mantovani C, et al · · 2023 · cited 11× · PMID 37760591 · DOI 10.3390/cancers15184622 -
Narrative Review of Synergistics Effects of Combining Immunotherapy and Stereotactic Radiation Therapy.
Lucia F, Geier M, Schick U, Bourbonne V. · · 2022 · cited 7× · PMID 35740435 · DOI 10.3390/biomedicines10061414 -
Is single fraction the future of stereotactic body radiation therapy (SBRT)? A critical appraisal of the current literature.
Terlizzi M, Limkin E, Sellami N, Louvel G, et al · · 2023 · cited 4× · PMID 36816840 · DOI 10.1016/j.ctro.2023.100584 -
Treatment of Brain Metastases: The Synergy of Radiotherapy and Immune Checkpoint Inhibitors.
Matsui JK, Perlow HK, Raj RK, Nalin AP, et al · · 2022 · cited 4× · PMID 36140312 · DOI 10.3390/biomedicines10092211
Verify or expand the search:
- PubMed search for NCT04427228
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Brain Cancer
Currently open trials in the same condition.
- NCT07374692 — Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors · NA · recruiting
- NCT06640582 — TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas · Phase 1, PHASE2 · recruiting
- NCT06058988 — Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer · Phase 2 · recruiting
- NCT05954858 — Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma · NA · recruiting
- NCT05943262 — Record Voxel Rate Nonlinear Optical Microscope to Unravel Brain Connectome and Signaling · recruiting
Other University of Chicago trials
Trials by the same sponsor.
- NCT07346196 — A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck · Phase 2 · not yet recruiting
- NCT07354100 — Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy · Phase 1, PHASE2 · not yet recruiting
- NCT06446661 — Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia · NA · not yet recruiting
- NCT07179315 — A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Tr · Phase 2 · not yet recruiting
- NCT07126561 — Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT04427228 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Chicago
- Last refreshed: 28 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04427228.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing